找回密码
 To register

QQ登录

只需一步,快速开始

扫一扫,访问微社区

Titlebook: Management of Hypertension; Current Practice and Vasilios Papademetriou,Emmanuel A. Andreadis,Chara Book 2019 Springer International Publis

[复制链接]
楼主: odometer
发表于 2025-3-23 11:05:35 | 显示全部楼层
发表于 2025-3-23 15:35:44 | 显示全部楼层
Arterial Hypertension and Cardiovascular Riskotal cardiovascular risk (i.e., the likelihood of developing a cardiovascular event, usually within the next 10 years), most of which are based either on the Framingham risk score or the European SCORE (Systemic Coronary Risk Evaluation) project. The 2013 ESH-ESC guidelines suggest subclinical organ
发表于 2025-3-23 19:36:05 | 显示全部楼层
The VA Co-operative Studies; The First RCTs in Cardiovascular Disease – A Tribute to Edward D. Freis], and the association continued to be strengthened by data from the same source accumulated over the next 3 decades. The beneficial effects of blood pressure reduction however, remained controversial till the mid 1950s because of the luck of effective therapies and the fear of harming vital organs
发表于 2025-3-23 22:17:21 | 显示全部楼层
发表于 2025-3-24 03:23:26 | 显示全部楼层
发表于 2025-3-24 07:47:14 | 显示全部楼层
Management of Hypertension in Diabetes Mellitusase) and microvascular (nephropathy, retinopathy) complications. Diabetes mellitus is associated with a two-fold to three-fold increased risk for cardiovascular events and is the leading cause of chronic kidney disease with almost half of end-stage renal disease cases being attributed to diabetes [1
发表于 2025-3-24 11:35:04 | 显示全部楼层
Chronic Kidney Disease and Hypertensionnetically susceptible individuals. The second most common cause of end-stage renal disease continues to be hypertension. Increased blood pressure participates in the pathogenesis of renal disease and the kidney is crucial in the long-term regulation of blood pressure. The development of hypertension
发表于 2025-3-24 17:36:57 | 显示全部楼层
发表于 2025-3-24 20:18:02 | 显示全部楼层
Comparison Therapies in the Treatment of Hypertension. The ASCOT and ACCOMPLISH Trialng interest, as in the majority of patients monotherapy does not achieve blood pressure control. Combination therapy seems safe, effective and convenient and several regimens are available in single-pill form, thereby facilitating compliance. Selection of the proper regimen remains a matter of debat
发表于 2025-3-25 02:15:02 | 显示全部楼层
 关于派博传思  派博传思旗下网站  友情链接
派博传思介绍 公司地理位置 论文服务流程 影响因子官网 SITEMAP 大讲堂 北京大学 Oxford Uni. Harvard Uni.
发展历史沿革 期刊点评 投稿经验总结 SCIENCEGARD IMPACTFACTOR 派博系数 清华大学 Yale Uni. Stanford Uni.
|Archiver|手机版|小黑屋| 派博传思国际 ( 京公网安备110108008328) GMT+8, 2025-6-7 14:45
Copyright © 2001-2015 派博传思   京公网安备110108008328 版权所有 All rights reserved
快速回复 返回顶部 返回列表